ChildStats.gov—Forum on Child and Family Statistics
faces of children
Home  |  About the Forum  |  Publications  |  Data Sources  |  Help
Search
HC3 Childhood immunization: Percentage of children ages 19–35 months vaccinated for selected diseases by poverty status,a and race and Hispanic origin,b 1996–2008

excel icon HC3 Excel Table

  Total Below 100% poverty 100% poverty and above
Characteristic 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008
Total
Combined Series (4:3:1:3:3:1)c — — — — — — 65.5 72.5 76.0 76.1 76.9 77.4 76.1 — — — — — — 61.6 69.7 72.6 73.9 73.4 75.0 72.4 — — — — — — 66.3 73.6 77.4 77.2 78.3 78.2 77.7
Combined Series (4:3:1:3:3)d 67.7 68.5 72.7 73.2 72.8 73.7 74.8 79.4 80.9 80.8 80.5 80.1 78.2 61.4 63.6 67.8 68.3 67.2 68.0 69.3 75.0 76.8 77.4 76.3 76.9 74.1 69.9 70.7 74.8 75.3 74.9 75.2 76.2 81.3 82.8 82.5 82.2 81.4 80.0
Combined series (4:3:1:3)e 76.4 76.2 79.2 78.4 76.2 77.2 77.5 81.3 82.5 82.4 82.1 81.8 79.6 68.9 70.7 74.1 73.3 70.5 71.5 71.8 76.2 78.0 79.2 77.8 78.8 75.4 79.2 78.9 81.5 80.7 78.3 78.9 79.0 83.3 84.6 84.1 83.9 82.9 81.4
Combined series (4:3:1)f 78.4 77.9 80.6 79.9 77.6 78.6 78.5 82.2 83.5 83.1 83.1 82.8 — 71.6 72.4 76.2 75.2 72.3 73.2 72.8 77.2 78.9 79.6 79.0 79.8 — 80.8 80.3 82.7 82.0 79.3 80.1 80.0 84.1 85.5 84.8 84.8 84.0 —
DTP (4 doses or more)g 81.1 81.5 83.9 83.3 81.7 82.1 81.6 84.8 85.5 85.7 85.2 84.5 85.0 73.9 75.8 79.5 78.5 76.2 76.5 75.4 79.7 81.2 81.8 80.8 81.1 76.8 83.6 83.9 86.1 85.4 83.5 83.6 83.5 86.8 87.4 87.4 86.9 85.9 86.5
Polio (3 doses or more)h 91.0 90.7 90.8 89.6 89.5 89.4 90.2 91.6 91.6 91.7 92.8 92.6 93.6 87.7 89.3 89.9 87.4 86.9 87.4 88.3 89.1 89.8 89.7 91.9 91.9 91.2 92.0 91.5 91.7 90.5 89.9 90.1 90.6 92.5 92.2 92.4 93.1 92.8 94.0
MMR (1 dose or more)i 90.6 90.4 92.0 91.5 90.5 91.4 91.6 93.0 93.0 91.5 92.3 92.3 92.1 87.2 85.7 90.1 90.0 88.9 89.1 90.2 92.0 91.3 89.3 90.9 91.3 90.2 91.9 92.0 93.1 92.4 90.9 91.9 91.9 93.4 93.5 92.1 93.0 92.6 91.5
Hib (3 doses or more)j 91.4 92.5 93.4 93.5 93.4 93.0 93.1 93.9 93.5 93.9 93.4 92.6 90.9 86.9 89.5 91.1 90.8 90.1 89.6 90.1 91.1 91.7 91.9 91.1 91.0 85.4 93.1 94.1 94.5 95.0 94.5 94.2 93.9 95.0 94.4 94.6 94.2 93.1 91.9
Hepatitis B (3 doses or more)k 81.8 83.6 87.0 88.1 90.3 88.9 89.9 92.4 92.4 92.9 93.3 92.7 93.5 78.0 80.7 85.3 86.5 87.3 86.5 87.7 91.1 91.4 91.4 92.7 92.1 90.7 83.2 84.9 87.7 89.0 91.4 89.5 90.3 93.2 92.8 93.5 93.5 92.9 93.9
Varicella (1 dose or more)l 12.2 25.8 43.2 57.5 67.8 76.3 80.6 84.8 87.5 87.9 89.2 90.0 90.7 5.4 16.9 40.5 55.4 63.5 74.0 78.9 84.4 86.4 87.3 88.3 89.2 87.5 15.3 29.1 44.1 58.2 69.2 77.1 80.9 85.0 87.5 87.7 90.0 90.1 90.4
PCV (3 doses or more)m — — — — — — 40.8 68.1 73.2 82.8 86.9 90.0 92.8 — — — — — — 33.2 62.2 69.0 78.3 84.1 89.0 88.5 — — — — — — 43.4 70.6 75.3 84.4 88.0 90.3 93.7
PCV (4 doses or more)m — — — — — — — — — 53.7 68.4 75.3 80.1 — — — — — — — — — 44.6 61.7 72.8 72.7 — — — — — — — — — 57.1 71.1 76.3 83.1
Hepatitis A (2 doses or more)n — — — — — — — — — — — — 40.4 — — — — — — — — — — — — 39.7 — — — — — — — — — — — — 40.8
White, non-Hispanic
Combined Series (4:3:1:3:3:1)c — — — — — — 66.2 73.9 77.2 76.0 77.8 77.5 75.3 — — — — — — 58.9 69.2 71.6 70.3 69.0 69.8 67.7 — — — — — — 67.0 74.5 78.0 77.2 78.9 78.5 76.8
Combined Series (4:3:1:3:3)d 68.9 70.4 75.6 75.6 76.0 75.2 77.7 82.5 83.3 82.1 82.2 81.0 77.8 59.3 64.3 71.8 70.9 69.8 67.7 70.0 77.4 76.5 76.3 74.1 73.0 70.0 70.5 71.4 76.1 76.3 77.0 76.2 78.4 83.1 84.3 83.4 83.1 82.0 79.3
Combined series (4:3:1:3)e 78.5 78.7 82.2 81.0 79.4 78.8 80.2 84.3 85.1 83.6 83.9 82.6 79.3 68.0 71.8 77.3 75.7 72.9 71.3 71.8 78.9 77.6 77.5 75.2 74.9 71.9 80.4 80.2 83.1 81.8 80.4 78.9 81.0 85.0 86.2 84.8 84.9 83.5 80.7
Combined series (4:3:1)f 80.1 80.2 83.3 82.0 80.3 79.9 81.2 85.0 85.7 84.0 84.7 83.3 — 70.3 73.3 78.5 77.1 73.6 71.9 73.0 79.9 78.0 77.7 76.7 75.2 — 81.9 81.7 84.1 82.8 81.3 81.0 82.0 85.6 86.9 85.3 85.7 84.3 —
DTP (4 doses or more)g 82.7 83.9 86.6 85.5 84.3 83.5 84.4 87.5 87.7 87.1 86.6 85.3 85.0 72.4 76.0 81.5 81.0 78.0 74.6 74.6 82.0 80.5 81.4 78.0 77.0 76.4 84.7 85.4 87.6 86.3 85.2 84.6 85.5 88.1 88.8 88.1 87.6 86.3 83.6
Polio (3 doses or more)h 91.9 91.5 92.2 90.3 90.6 90.1 91.2 93.0 92.1 91.4 93.3 92.6 93.6 88.2 90.3 90.9 87.7 87.7 87.4 88.0 90.8 88.3 87.4 90.1 86.1 90.2 92.5 92.0 92.6 90.8 90.9 90.5 91.5 93.3 92.6 92.3 93.6 93.5 91.9
MMR (1 dose or more)i 91.4 91.4 93.1 92.4 91.5 91.7 92.6 93.2 93.5 91.4 92.8 92.1 91.3 85.1 84.3 90.4 90.3 88.4 87.2 90.4 89.7 89.9 86.7 87.7 88.3 92.3 92.5 92.7 93.7 92.8 91.6 92.2 92.9 93.5 94.1 92.1 93.5 92.4 91.9
Hib (3 doses or more)j 92.8 93.9 95.0 94.8 94.7 94.2 94.1 95.1 94.7 94.2 94.1 92.9 90.8 87.4 89.9 92.2 92.5 92.2 89.2 88.4 90.9 92.1 89.4 87.9 86.7 86.0 93.7 94.7 95.5 95.2 95.1 94.7 94.7 95.7 95.1 95.1 94.8 93.8 91.1
Hepatitis B (3 doses or more)k 82.1 84.6 88.3 88.9 91.4 89.6 90.9 93.2 93.0 93.1 93.8 92.5 93.4 76.4 80.4 87.2 87.8 87.8 86.0 85.9 90.6 91.6 90.2 91.7 87.8 90.5 83.3 84.9 88.3 89.0 91.9 89.9 91.5 93.6 93.1 93.6 94.0 93.2 93.4
Varicella (1 dose or more)l 14.5 27.5 41.9 56.0 66.4 74.7 79.4 83.8 86.5 86.1 88.7 89.2 89.8 6.4 16.5 37.5 50.7 58.4 67.1 75.0 79.5 83.7 82.3 83.2 85.1 89.9 16.3 29.3 42.8 56.6 67.8 75.7 80.2 84.6 86.9 86.6 89.4 89.8 91.1
PCV (3 doses or more)m — — — — — — 43.5 70.9 75.3 83.2 87.2 89.8 92.8 — — — — — — 31.3 58.8 65.7 76.4 79.5 84.9 89.8 — — — — — — 45.6 72.7 77.1 84.3 88.4 90.4 92.2
PCV (4 doses or more)m — — — — — — — — — 57.3 70.9 76.6 81.4 — — — — — — — — — 46.6 60.0 69.4 72.8 — — — — — — — — — 59.3 72.4 77.6 80.6
Hepatitis A (2 doses or more)n — — — — — — — — — — — — 37.6 — — — — — — — — — — — — 31.1 — — — — — — — — — — — — 39.1
Black, non-Hispanic
Combined Series (4:3:1:3:3:1)c — — — — — — 61.7 68.4 70.9 76.3 73.8 75.3 72.7 — — — — — — 59.3 63.7 68.1 73.5 71.7 74.4 70.2 — — — — — — 62.1 71.9 74.6 80.1 76.8 76.5 74.9
Combined Series (4:3:1:3:3)d 66.8 65.6 66.6 69.4 68.2 67.1 67.7 73.0 74.5 79.3 76.7 77.5 74.2 61.3 63.8 66.9 66.9 66.8 65.0 65.9 68.9 72.0 75.8 74.0 75.9 71.0 71.9 69.5 67.5 72.9 69.5 68.6 68.3 76.8 78.2 83.0 80.4 79.6 77.3
Combined series (4:3:1:3)e 74.2 72.8 72.9 73.8 70.6 71.4 70.7 75.2 76.0 80.5 78.4 79.5 75.8 69.3 71.1 71.9 72.4 68.5 68.7 68.4 70.2 73.8 76.8 75.8 77.9 72.7 79.1 76.5 74.1 76.7 72.2 74.1 71.7 78.8 79.6 83.8 81.9 82.0 78.6
Combined series (4:3:1)f 76.6 74.0 74.3 75.1 71.5 72.8 71.6 76.7 77.8 81.4 78.9 81.0 — 72.5 72.0 73.6 73.8 69.6 70.7 69.3 71.6 76.0 77.8 76.5 79.7 — 80.9 77.7 75.7 77.9 73.2 75.1 72.6 80.2 81.2 84.2 82.4 83.4 —
DTP (4 doses or more)g 79.0 77.2 77.3 79.0 76.4 76.3 75.8 79.9 79.5 84.0 81.2 82.3 80.1 74.3 75.9 77.0 77.9 74.5 74.2 73.5 74.6 77.8 79.7 78.8 81.0 82.2 83.3 80.0 78.8 82.5 78.0 78.1 77.3 83.9 82.8 87.5 84.8 84.2 87.7
Polio (3 doses or more)h 90.1 89.1 87.8 87.0 86.8 84.9 87.4 89.2 90.4 91.0 90.4 91.1 91.5 86.8 89.2 88.3 86.2 85.1 84.3 87.0 86.0 89.5 89.0 90.4 91.2 92.5 92.6 90.5 86.9 88.4 87.1 86.1 87.1 91.4 91.1 92.6 91.4 91.3 96.3
MMR (1 dose or more)i 89.7 89.0 88.8 89.8 87.9 89.1 90.3 92.1 90.7 91.9 90.9 91.5 92.0 88.3 87.0 88.8 90.2 88.4 88.3 89.8 91.3 90.1 91.3 90.8 90.2 92.8 90.8 91.3 89.8 90.9 87.3 89.9 90.2 92.5 91.3 92.8 91.6 93.4 92.6
Hib (3 doses or more)j 89.4 91.4 90.1 91.8 92.8 89.5 91.6 92.4 90.9 92.9 91.0 90.8 88.6 85.9 91.0 90.3 90.7 91.9 87.1 88.3 90.0 89.6 91.6 89.9 89.4 90.1 92.8 93.7 89.6 94.1 93.4 91.3 93.9 94.6 92.3 94.8 93.4 92.2 93.6
Hepatitis B (3 doses or more)k 81.9 82.0 83.7 86.5 89.2 84.9 88.0 91.6 90.8 92.7 91.5 91.2 92.1 77.8 81.9 86.1 85.6 88.6 84.7 88.6 91.5 89.2 92.7 91.6 91.6 91.6 85.0 84.3 82.8 89.9 90.2 85.3 87.7 92.2 92.1 94.1 92.5 91.0 95.8
Varicella (1 dose or more)l 8.6 20.8 42.4 57.6 67.3 75.3 82.7 85.4 86.3 90.6 89.1 89.8 90.4 — 15.7 40.1 57.1 60.2 71.3 79.7 83.7 85.2 91.0 89.2 89.3 91.1 12.9 27.1 44.4 60.4 72.1 77.1 83.6 86.1 87.4 90.8 89.8 90.8 92.7
PCV (3 doses or more)m — — — — — — 33.9 62.3 68.2 79.6 82.9 89.5 90.9 — — — — — — 30.2 61.3 66.5 76.8 82.2 87.8 92.5 — — — — — — 37.5 63.7 69.6 82.2 84.5 91.4 95.7
PCV (4 doses or more)m — — — — — — — — — 46.2 60.5 70.3 76.4 — — — — — — — — — 42.7 56.6 66.1 74.9 — — — — — — — — — 48.1 64.8 74.4 82.3
Hepatitis A (2 doses or more)n — — — — — — — — — — — — 39.7 — — — — — — — — — — — — 38.7 — — — — — — — — — — — — 40.7
Hispanic
Combined Series (4:3:1:3:3:1)c — — — — — — 66.0 71.3 75.9 75.6 77.0 78.0 77.7 — — — — — — 66.0 73.1 75.0 75.6 76.4 77.7 74.9 — — — — — — 65.5 70.3 77.5 74.8 78.3 78.5 80.5
Combined Series (4:3:1:3:3)d 63.7 65.7 68.7 69.6 68.5 74.1 72.7 77.0 79.7 78.8 79.7 79.8 79.4 62.4 62.2 65.1 68.0 66.2 69.8 71.8 76.8 78.9 78.3 78.3 79.0 76.6 64.1 69.8 73.3 72.9 70.3 75.7 72.9 78.3 81.7 79.1 81.6 80.9 82.1
Combined series (4:3:1:3)e 71.1 72.6 75.3 74.9 72.7 77.0 75.5 78.7 81.2 81.2 81.3 81.5 80.7 68.2 69.6 72.9 73.3 69.9 73.1 74.8 77.6 79.8 80.9 80.1 80.9 77.5 72.7 76.7 79.1 78.4 74.1 78.8 75.6 80.6 83.5 81.9 83.2 82.5 83.9
Combined series (4:3:1)f 74.1 74.5 77.2 77.3 74.8 79.0 76.5 79.3 82.2 81.8 82.0 82.4 — 70.9 71.1 75.5 75.6 73.1 75.5 75.6 78.7 80.3 81.0 80.9 81.9 — 74.6 77.4 80.2 80.1 75.1 79.7 76.6 80.9 84.3 82.7 83.9 83.5 —
DTP (4 doses or more)g 77.2 77.7 80.5 80.2 78.6 82.5 79.2 81.9 84.1 83.6 84.5 83.8 84.9 74.0 74.9 79.0 77.9 76.1 79.1 77.9 81.1 82.5 82.5 82.7 82.9 82.2 77.5 80.6 83.2 82.4 79.9 83.1 79.7 83.5 86.0 84.9 86.3 85.2 87.7
Polio (3 doses or more)h 89.4 89.7 88.9 89.4 87.9 90.7 90.4 90.1 91.2 92.3 93.3 93.0 94.3 88.0 88.4 90.1 88.8 87.7 89.6 89.3 89.3 90.1 91.5 93.0 95.3 92.5 89.8 90.2 90.3 89.9 86.9 91.1 90.7 91.5 92.2 92.3 93.4 90.4 96.3
MMR (1 dose or more)i 88.2 88.4 91.0 90.2 90.0 92.1 90.5 92.7 93.2 91.1 92.0 92.6 92.8 87.4 85.2 90.4 89.9 90.0 90.5 90.8 93.4 92.1 89.5 92.8 92.9 92.8 89.0 89.5 92.3 91.3 90.0 92.7 89.0 93.4 93.5 91.4 91.9 92.1 92.6
Hib (3 doses or more)j 88.5 90.0 91.7 92.0 91.1 92.5 92.4 93.1 92.6 94.2 93.9 93.5 91.9 87.1 89.0 91.8 90.7 87.7 91.3 93.1 91.7 91.8 93.6 93.5 93.9 90.1 90.3 92.3 93.5 95.1 93.3 94.4 92.2 95.1 94.4 93.9 93.9 92.9 93.6
Hepatitis B (3 doses or more)k 80.8 81.2 85.7 87.3 88.2 89.8 89.5 91.2 91.9 92.7 93.6 93.6 93.7 79.9 78.8 83.1 86.5 86.7 88.1 89.0 90.7 91.3 91.5 93.2 94.5 91.6 81.1 84.4 88.3 88.9 89.7 91.0 88.9 92.8 92.9 92.8 93.9 92.6 95.8
Varicella (1 dose or more)l 7.6 22.4 46.9 60.5 70.2 80.3 81.8 85.7 89.1 89.2 89.6 90.6 91.8 6.3 17.6 44.0 58.6 69.9 80.7 82.4 87.8 88.1 88.4 90.5 91.2 91.1 11.2 25.3 48.8 61.7 69.8 81.8 80.6 84.7 89.4 88.8 90.5 89.3 92.7
PCV (3 doses or more)m — — — — — — 37.4 65.5 70.4 83.5 88.9 91.0 94.1 — — — — — — 35.1 65.1 71.2 80.0 87.7 91.6 92.5 — — — — — — 37.6 67.4 71.4 86.0 89.8 90.3 95.7
PCV (4 doses or more)m — — — — — — — — — 50.5 67.4 75.4 78.6 — — — — — — — — — 44.7 64.9 77.5 74.9 — — — — — — — — — 53.8 70.2 73.3 82.3
Hepatitis A (2 doses or more)n — — — — — — — — — — — — 44.7 — — — — — — — — — — — — 43.9 — — — — — — — — — — — — 44.6
— Not available.
a Based on family income and household size using U.S. Bureau of Census poverty thresholds for the year of data collection.
b From 1996 to 2001, the 1977 OMB Standards for Data on Race and Ethnicity were used to classify persons into one of the following racial groups: White, Black, American Indian or Alaskan Native, or Asian or Pacific Islander. Beginning in 2002, the revised 1997 OMB Standards for Data on Race and Ethnicity were used. Persons could select one or more from the following racial groups: White, Black or African American, American Indian or Alaska Native, Asian, or Native Hawaiian or Other Pacific Islander. Persons of Hispanic origin may be of any race. Included in the total but not shown separately are American Indian or Alaska Native, Asian, Native Hawaiian or Other Pacific Islander and "Two or more races" due to the small sample size. Data on race and Hispanic origin are collected separately but combined for reporting.
c The 4:3:1:3:3:1 series consists of 4 doses (or more) of diphtheria, tetanus toxoids, and pertussis (DTP) vaccines, diphtheria and tetanus toxoids (DT), or diphtheria, tetanus toxoids, and any acellular pertussis (DTaP) vaccines; 3 doses (or more) of poliovirus vaccines; 1 dose (or more) of any measles-containing vaccine; 3 doses (or more) of Haemophilus influenzae type b (Hib) vaccines; 3 doses (or more) of hepatitis B vaccines; and 1 dose (or more) of varicella vaccine. The collection of coverage rate estimates for this series began in 2002.
d The 4:3:1:3:3 series consists of 4 doses (or more) of diphtheria, tetanus toxoids, and pertussis (DTP) vaccines, diphtheria and tetanus toxoids (DT), or diphtheria, tetanus toxoids, and any acellular pertussis (DTaP) vaccines; 3 doses (or more) of poliovirus vaccines; 1 dose (or more) of any measles-containing vaccine; 3 doses (or more) of Haemophilus influenzae type b (Hib) vaccines; and 3 doses (or more) of hepatitis B vaccines.
e The 4:3:1:3 series consists of 4 doses (or more) of diphtheria, tetanus toxoids, and pertussis (DTP) vaccines, diphtheria and tetanus toxoids (DT), or diphtheria, tetanus toxoids, and any acellular pertussis (DTaP) vaccines; 3 doses (or more) of poliovirus vaccines; 1 dose (or more) of any measles-containing vaccine; and 3 doses (or more) of Haemophilus influenzae type b (Hib) vaccines.
f The 4:3:1 series consists of 4 doses (or more) of diphtheria, tetanus toxoids, and pertussis (DTP) vaccines, diphtheria and tetanus toxoids (DT), or diphtheria, tetanus toxoids, and any acellular pertussis (DTaP) vaccines, 3 doses (or more) of poliovirus vaccines; and 1 dose (or more) of any measles-containing vaccine.
g Diphtheria, tetanus toxoids, and pertussis vaccine (4 doses or more of any diphtheria, tetanus toxoids, and pertussis vaccines, including diphtheria and tetanus toxoids, and any acellular pertussis vaccine).
h Poliovirus vaccine (3 doses or more).
i Measles-mumps-rubella (MMR) vaccine (1 dose or more) was used beginning in 2005. The previous coverage years reported measles-containing vaccines.
j Haemophilus influenzae type b (Hib) vaccine (3 doses or more).
k Hepatitis B vaccine (3 doses or more).
l Varicella vaccine (1 dose or more) is recommended at any visit at or after age 12 months for susceptible children (i.e., those who lack a reliable history of chickenpox).
m The heptavalent pneumococcal conjugate vaccine (PCV) is recommended for all children aged less than 5 years. The series consists of doses at ages 2, 4, and 6 months, and a booster dose at ages 12–15 months.
n Hepatitis A vaccine (2 doses or more) is recommended for all children ages 12–23 months. The ACIP expanded this recommendation in May, 2006. NIS data prior to 2008 for children aged 19–35 months is not available for Hepatitis A vaccine.
SOURCE: Centers for Disease Control and Prevention, National Center for Immunization and Respiratory Diseases and National Center for Health Statistics, National Immunization Survey.